AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 64 filers reported holding AVROBIO INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,000 | -80.0% | 1,333 | -73.0% | 0.00% | – |
| Q2 2022 | $5,000 | +150.0% | 4,928 | +296.8% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 1,242 | +148.4% | 0.00% | – |
| Q4 2021 | $2,000 | -99.6% | 500 | -99.4% | 0.00% | – |
| Q3 2021 | $468,000 | -48.3% | 83,837 | -17.8% | 0.00% | – |
| Q2 2021 | $906,000 | -74.0% | 101,954 | -62.9% | 0.00% | – |
| Q1 2021 | $3,490,000 | -55.9% | 275,054 | -51.5% | 0.00% | -100.0% |
| Q4 2020 | $7,910,000 | +34.7% | 567,454 | +25.8% | 0.00% | 0.0% |
| Q3 2020 | $5,874,000 | -56.7% | 451,154 | -41.9% | 0.00% | 0.0% |
| Q2 2020 | $13,553,000 | +12.1% | 776,654 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $12,085,000 | +173.9% | 776,654 | +254.4% | 0.00% | – |
| Q4 2019 | $4,412,000 | +159.4% | 219,170 | +82.0% | 0.00% | – |
| Q3 2019 | $1,701,000 | -76.2% | 120,443 | -12.7% | 0.00% | -100.0% |
| Q3 2018 | $7,153,000 | -49.9% | 137,900 | -72.4% | 0.00% | -50.0% |
| Q2 2018 | $14,280,000 | – | 500,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |